Angela Papalamprou

Angela Papalamprou

Auto-generated profile, based on publicly available information

Angela Papalamprou

Orthopaedic Stem Cell Research Laboratory, Cedars-Sinai Medical Center

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2023 in Journal of Orthopaedic Research
Verified
Journal Article
Closed access
GKGiselle Kaneda
Giselle Kaneda
JCJulie Lynn Chan
Julie Lynn Chan
CCChloe M. Castaneda
Chloe M. Castaneda
APAngela Papalamprou
Angela Papalamprou
JSJulia Sheyn
Julia Sheyn
DSDmitriy Sheyn
Dmitriy Sheyn

26 October 2022 in Journal of Orthopaedic Research
Verified
Journal Article
Closed access
APAngela Papalamprou
Angela Papalamprou
VYVictoria Yu
Victoria Yu
ACAngel Chen
Angel Chen
TSTina Stefanovic
Tina Stefanovic
GKGiselle Kaneda
Giselle Kaneda
DSDmitriy Sheyn
Dmitriy Sheyn

21 May 2026 in eLife
Verified
Journal Article
Open access
APAngela Papalamprou
Angela Papalamprou
VYVictoria Yu
Victoria Yu
WJWensen Jiang
Wensen Jiang
JSJulia Sheyn
Julia Sheyn
TSTina Stefanovic
Tina Stefanovic
DSDmitriy Sheyn
Dmitriy Sheyn
During vertebrate embryogenesis, axial tendons develop from the paraxial mesoderm and differentiate through specific developmental stages to reach the syndetome stage. While the main roles of signaling pathways in the earlier stages of differentiation have been well established, pathway nuances in syndetome specification from the sclerotome stage have yet to be explored. Here, stepwise differentiation of human induced pluripotent stem cells to the syndetome stage is shown, using chemically defined media and small molecules that were modified based on single-cell RNA-sequencing and pathway analysis. A significant population of branching off-target cells differentiating toward a neural phenotype overexpressing Wnt was identified. Further transcriptomics post-addition of a WNT inhibitor at the somite stage and onwards revealed not only total removal of the neural off-target cells, but also increased syndetome induction efficiency. Fine-tuning tendon differentiation in vitro is essential to address the current challenges in developing a successful cell-based tendon therapy.

23 November 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
APAngela Papalamprou
Angela Papalamprou
VYVictoria Yu
Victoria Yu
ACAngel Chen
Angel Chen
TSTina Stefanovic
Tina Stefanovic
GKGiselle Kaneda
Giselle Kaneda
DSDmitriy Sheyn
Dmitriy Sheyn
Regenerative therapies for tendon are falling behind other tissues due to the lack of an appropriate and potent cell therapeutic candidate. This study aimed to induce cell tenogenesis using stable Scleraxis (Scx) overexpression in combination with uniaxial mechanical stretch of mesenchymal stromal cells (MSCs) of different origins. Scleraxis (Scx) is the single direct molecular regulator of tendon differentiation known to date. Mechanoregulation is known to be a central element guiding tendon development and healing. Cells explored were bone marrow-derived (BM-)MSCs as well as MSCs differentiated from induced pluripotent stem cells (iMSCs). Mechanical stimulation combined with Scx overexpression resulted in morphometric and cytoskeleton-related changes, upregulation of early and late tendon markers, increased ECM deposition and alignment, and tenomodulin perinuclear localization in iMSCs, which was greater compared to BM-MSCs and controls. Our findings suggest that these cells can be differentiated into tenocytes and may be a better candidate for tendon cell therapy applications than BM-MSCs.